Synthetic vitamin D receptor ligands reduce murine kidney fibrosis

Vitamin D deficiency has been associated with kidney disease including fibrosis. Some studies have even suggested that treatment with vitamin D or vitamin D analogs can reduce renal fibrosis; however, the pathways targeted by vitamin D therapy are not completely understood.

In this issue of the Journal of Clinical Investigation, Junn Yanagisawa and colleagues at the University of Tsukuba found that D binding to its receptor inhibited the TGF-β/SMAD signaling pathway and prevented renal fibrosis in mice.

The authors then generated a synthetic ligand of the vitamin D receptor that, like vitamin D, reduced renal fibrosis; however, unlike vitamin D, this synthetic ligand did not promote hypercalcemia.

In the accompanying commentary Joseph Bonventre suggests that synthetic ligands of the vitamin D receptor should be further studied as therapeutics for patients with fibrotic diseases.


Explore further

Can vitamin B supplements help stave off stroke?

More information: A nonclassical vitamin D receptor pathway suppresses renal fibrosis, J Clin Invest. DOI: 10.1172/JCI67804
Antifibrotic vitamin D analogs, J Clin Invest. 2013;123(11):4570–4573. DOI: 10.1172/JCI72748
Citation: Synthetic vitamin D receptor ligands reduce murine kidney fibrosis (2013, October 25) retrieved 25 June 2019 from https://medicalxpress.com/news/2013-10-synthetic-vitamin-d-receptor-ligands.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more